TSH-Receptor-Antibodies (TSHR-AB) Help to Predict Severity and Outcome of Graves Ophthalmopathy (GO)
Eckstein A.1, Plicht M.1, Morgenthaler N.4, Steuhl K. P.1, Renzing-Köhler K.3, Quadbeck B.2, Mann K.2, Esser J.1
1Department of Ophthalmology, 2Department of Medicine, Division of Endocrinology, 3Institute for Medical Informatics, Biometry and Epidemiology, University Essen; 4BRAHMS AG, Research, Biotechnology Centre Hennigsdorf/Berlin, Germany
Purpose: There are no useful biomarkers known to assess the prognosis of the GO, which makes the management of GO very difficult. The association between TSHR-AB and GO is still a mater of debate. The aim of this study was to evaluate the value of TSHR-AB for the prognosis of GO by the retrospective analysis of prospectively collected follow up data of GO patients.
Method: 67 patients with GO have been followed for two years. Patients were divided into two groups (according to the course of the clinical activity score (CAS) and the severity the disease: modified NOSPECS score). Severe GO (n=30): CAS >8, NOSPECS >7 at first visit, CAS 4-7, NOSPECS 3-6 at first visit with increasing or unchanging values, CAS <4, NOSPECS <3 at first visit and increasing values. Mild to moderate GO(n=37): CAS 4-7, NOSPECS 3-6 at first visit with decreasing values or CAS <4, NOSPECS <3 at first visit with maintaining or decreasing values. TSHR-AB (TBII, TRAKhuman, BRAHMS, Germany) were measured w
Zurück | Back